Gastrointestinal Stromal Tumour (GIST) from the Surgical Point of View;Gastrointestinale Stromatumoren (GIST) aus Chirurgischer Sicht

Viszeralchirurgie

Volumn 38, Issue 6, 2003, Pages 374-378

  Langer, Claus ^a   Schuler P ^a   Gunawan, P ^a   Von Heydebreck, A ^b   Schaper, A ^a   Liersch, T ^a   Schindler, C G ^a   Fuzesi L ^a   Becker, H ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

Author keywords

Adjuvant neoadjuvant therapy; CD117 (KIT); Gastrointestinal stromal tumour; Imatinib; Prognosis; Tyrosine kinase inhibition

Indexed keywords

IMATINIB; STEM CELL FACTOR;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RISK; CANCER SURGERY; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SURGERY; GENETIC RISK; HUMAN; METASTASIS; MORPHOMETRICS; MULTIMODALITY CANCER THERAPY; PROGNOSIS; SIDE EFFECT;

EID: 0346024220     PISSN: 14353067     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-45510     Document Type: Article

References (29)

1. Reichert P, Pink D, Hohenberger P. Paradigmawechsel in der Therapie gastrointestinaler Stromatumoren. Onkologe 2002; 8: 378-383
2. Sarkomo-Rikala M, Kovatich AJ, Barusevisius A, Miettinen M. CD117. A sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998; 11: 728-734
3. Miettinen M, Monihan JM, Sarkomo-Rikala M, Kovatich AJ, Carr NJ, Emory TS, Sobin LH. Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Pathol 1999; 23: 1109-1118
4. Reith JD, Goldblum JR, Lyles RH, Weiss SW. Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol 2000; 13: 577-585
5. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152: 1259-1269
6. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580
7. Sakurai S, Fukasawa T, Chong JM, Tanaka A, Fukayama M. C-kit gene abnormalities in gastrointestinal stromal tumors (tumors of interstitial cells of Cajal). Jpn J Cancer Res 1999; 90: 1321-1328
8. Gunawan B, Bergmann F, Höer J, Langer C, Schumpelick V, Becker H, Füzesi L. Biological and clinical significance of cytogenetic abnormalities in low-risk and high-risk gastrointestinal stromal tumors. Hum Pathol 2002; 33: 316-321
9. Langer C, Gunawan B, Schüler P, Huber W, Füzesi L. Becker H. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours. Br J Surg 2003; 90: 332-339
10. DeMatteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI571. Hum Pathol 2002; 33: 466-477
11. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-1042
12. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Ziegler AJ. Inhibition of c.kit receptor tyrosine kinase activity be STI571, a selective tyrosine kinase inhibitor. Blood 2000; 96: 925-932
13. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al. Effect of the tyrosine kinase inhibitor ST1571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-1056
14. Miettinen M, El-Rifai W, Sobin LH, Lasota J. Evaluation of Malignancy and Prognosis of Gastrointestinal Stromal Tumors: A Review. Hum Pathol 2002; 33: 478-483
15. Emory TS, Sobin LH, Lukes L, Lee DH, O'Leary TJ. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999; 23: 82-87
16. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999; 30: 1213-1220
17. Franquemont DW. Differentiation and risk assessment of gastrointestinal stromal tumors. Am J Clin Pathol 1995; 103: 41-47
18. Fletcher C, Berman JJ, Corless C, et al. Diagnosis of Gastrointestinal Stromal Tumors: A Consensus Approach. Hum Pathol 2002; 33: 459-465
19. Pierie JP, Choudry U, Muzikansky A, Yeap BY, Souba WW, Ott MJ. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 2001: 136: 383-389
20. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001; 61: 8118-8121
21. Fong Y, Coit DG, Woodruff JM, Brennan MF. Lymph Node Metastasis From Soft Tissue Sarcoma in Adults. Ann Surg 1993; 217: 72-77
22. De Matteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-58
23. Ng E-H, Pollock RE, Munsell MF, Atkinson EN, Romsdahl MM. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992; 215: 68-77
24. Hohenberger P, Reichardt P, Stroszczynski C, Schneider U, Hossfeld DK. Gastrointestinale Stromatumoren - Tumorentität und Therapie mit Imatinib. Deutsches Ärzteblatt 2003; 100 (23): 1334-1339
25. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advances gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480
26. van Oosterom AT, Judson I, Verweji J, Stroobants S, Donato-di-Paola E, Dimitrijevic S, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: a phase I study. Lancet 2001; 358: 1421-1423
27. Mudan SS, Conlon KC, Woodruff JM, Lewis JJ, Brennan MF. Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Cancer 2000; 88: 66-74
28. Bümming P, Andersson J, Meiss-Kindblom JM, et al. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. Br J Cancer 2003; 89: 460-464
29. El-Rifai W, Sarlomo-Rikala M, Andersson LC, Knuutila S, Miettinen M. DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance. Cancer Res 2000: 60: 3899-3903